Cleveland Biolabs Inc (NASDAQ:CBLI)

3.56
Delayed Data
As of Mar 27
 +0.01 / +0.28%
Today’s Change
3.07
Today|||52-Week Range
16.20
-37.54%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$12.2M

Company Description

Cleveland BioLabs, Inc. is a clinical-stage biotechnology company with a focus on oncology and acute radiation syndrome drug development. It is engaged in the research, development and commercialization of products that have the potential to treat cancer, reduce death from total body irradiation and counteract the toxic effects of radio and chemotherapies for oncology patients. The company has designed two oppositely-directed general therapeutic concepts: temporary and reversible suppression of apoptosis in normal cells to protect healthy tissues from stress-induced damage using compounds categorized as Protectans; and reactivation of apoptosis in tumor cells to eliminate cancer using compounds categorized as Curaxins. The company was founded by Andrei V. Gudkov on June 5, 2003 and is headquartered in Buffalo, NY.

Contact Information

Cleveland BioLabs, Inc.
73 High Street
Buffalo New York 14203
P:(716) 849-6810
Investor Relations:
(646) 284-9439

Employees

Shareholders

Mutual fund holders2.82%
Other institutional2.70%
Individual stakeholders0.39%

Top Executives

Yakov KoganChief Executive Officer & Director
Leah BrownleeSecretary, VP-Compliance & Operations
C. Neil LyonsCFO, Head-Investor & Public Relations
Andrei V. GudkovDirector & Chief Scientific Officer
Michael R. KurmanChief Medical Officer

To view my watchlist

Not a member yet?

Sign up now for a free account